• Zai Lab flagged first global results from a trial of zocilurtatug pelitecan for first-line extensive-stage small cell lung cancer.
• Data have not been released yet; an ESMO Congress 2026 poster is scheduled for Oct. 26 in Madrid.
• The study tests the DLL3-targeting antibody-drug conjugate with atezolizumab, with or without carboplatin.
• Zai Lab framed the readout as supportive of zocilurtatug pelitecan as a potential backbone therapy in first-line combinations.
• An investor call is set for Oct. 23 to discuss the ESMO presentation and the program’s next clinical steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609290700BIZWIRE_USPR_____20260929_BW210432) on September 29, 2026, and is solely responsible for the information contained therein.